Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vsResMed Inc (RMD)
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
$3.13
+6.28%
HEALTHCARE · Cap: $7.96M
RMD
ResMed Inc
$235.76
+0.03%
HEALTHCARE · Cap: $34.00B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 11331716% more annual revenue ($5.65B vs $49,890). RMD leads profitability with a 27.0% profit margin vs 0.0%. RMD earns a higher WallStSmart Score of 65/100 (C+).
CUPR
Avoid30
out of 100
Grade: F
RMD
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CUPR.
Margin of Safety
-24.0%
Fair Value
$209.33
Current Price
$235.76
$26.43 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 267.4% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 30.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Generating 1.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -92.4% — below average capital efficiency
2.4% earnings growth
Comparative Analysis Report
WallStSmart ResearchBull Case : CUPR
The strongest argument for CUPR centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 267.4% demonstrates continued momentum.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 30.9%. PEG of 1.37 suggests the stock is reasonably priced for its growth.
Bear Case : CUPR
The primary concerns for CUPR are EPS Growth, Market Cap, Profit Margin.
Bear Case : RMD
The primary concerns for RMD are EPS Growth.
Key Dynamics to Monitor
CUPR profiles as a hypergrowth stock while RMD is a mature play — different risk/reward profiles.
CUPR is growing revenue faster at 267.4% — sustainability is the question.
RMD generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RMD scores higher overall (65/100 vs 30/100), backed by strong 27.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?